"The EMA's (European Medicines Agency) Committee for Medicinal Products for Human Use(CHMP) granted sipavibart accelerated assessment as it was deemed of major interest for public health and therapeutic innovation," the Anglo-Swedish drugmaker said.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/txrXzfW
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment